Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
In preclinical models, MCLA-158 binding triggers EGFR degradation in LGR5+ CSCs and is designed to have two different mechanisms of action. The first entails blocking of growth and survival pathways in cancer initiating cells.
Lead Product(s): Petosemtamab
Therapeutic Area: Oncology Product Name: MCLA-158
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Merus
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021